

# samumed news

February 2019

## Osteoarthritis (OA) Program Update



- We had a positive and constructive end-of-phase 2 meeting with the FDA, and we will initiate our pivotal phase 3 trials shortly
- We publicly disclosed the biological targets and the mechanism of action for our OA program for the first time

## Corporate News



- Our team size is now over 200 full-time employees
- We signed the lease for our new facilities to accommodate our continued growth